STOCK TITAN

Augmedix Inc - AUGX STOCK NEWS

Welcome to our dedicated news page for Augmedix (Ticker: AUGX), a resource for investors and traders seeking the latest updates and insights on Augmedix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Augmedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Augmedix's position in the market.

Rhea-AI Summary
Augmedix launches Augmedix Go, the industry’s first fully-automated, GenAI-powered medical documentation product for emergency departments. The product aims to improve patient experience, increase productivity, reduce cognitive burden, and shorten chart closure time. Augmedix Go was piloted with HCA Healthcare EDs, receiving positive feedback on note quality and AI accuracy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) partners with Andor Health to enhance virtual care with ambient AI medical documentation, aiming to improve clinician-patient interactions and streamline workflows. The collaboration integrates AI-generated clinical notes within ThinkAndor® Virtual Visit, leveraging ambient documentation to transform care settings. Augmedix and Andor Health aim to optimize communication, reduce clinician burnout, and enhance patient outcomes through their innovative platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) partners with SADA, an Insight company, to accelerate digital health solutions and integrations. The collaboration aims to enhance ambient AI medical documentation and data products for health systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
Augmedix (AUGX) reports impressive financial results for Q4 and full year 2023, showcasing revenue growth of 45% to $12.7 million and $44.9 million respectively. The company achieved a gross profit increase of 54% to $6.2 million and $21.5 million for the respective periods. Augmedix anticipates revenue of $60 to $62 million in 2024, reflecting strong growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.92%
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) announces positive data and product enhancements for Augmedix Go, saving clinicians up to 1 hour per day in medical documentation. The app supports over 50 medical specialties, generating real-time draft notes from natural conversations. Survey data shows 94% of clinicians report better patient focus. Augmedix Go integrates with major EHRs and uses AI models for high-quality notes. CEO Manny Krakaris emphasizes the need for automated solutions to combat administrative burden and burnout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
AI
-
Rhea-AI Summary
Augmedix (Nasdaq: AUGX) to Release Q4 and Full Year 2023 Results on March 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
Rhea-AI Summary
Augmedix, Inc. (Nasdaq: AUGX) will participate in the Citizens JMP Technology Conference in San Francisco on March 4, 2024. The management team will host a fireside chat and investor meetings, accessible through a webcast on the Company's IR website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
conferences
-
Rhea-AI Summary
Augmedix appoints Tomer Levy as Senior Vice President of Engineering to enhance product development and operational efficiency in healthcare technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
none
-
Rhea-AI Summary
Augmedix, Inc. (AUGX) to participate in Maxim Group Virtual Healthcare IT Conference on January 24, 2024. Manny Krakaris, CEO, to join fireside chat with Allen Klee, Equity Research Analyst. Investors can arrange meetings through FNK IR or Maxim Group representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
Rhea-AI Summary
Augmedix, Inc. (Nasdaq: AUGX) expects fourth quarter 2023 revenue to be above guidance, with approximately $12.5 million, leading to a full-year 2023 revenue of about $44.7 million. The company also anticipates an annual recurring revenue of $51 million, a 46% increase from the previous year, and has seen a 41% year-over-year increase in clinicians in service. Augmedix Go, the company's latest product, is now generally available in the ambulatory setting. The CEO, Manny Krakaris, expressed confidence in the company's growth plans and its ability to unburden clinicians and improve healthcare organizations' operating efficiency. Additionally, the company expects to report financial results for the fourth quarter of 2023 in March.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
Augmedix Inc

Nasdaq:AUGX

AUGX Rankings

AUGX Stock Data

168.15M
28.91M
10.17%
76.81%
1.71%
All Other Business Support Services
Administrative and Support and Waste Management and Remediation Services
Link
United States
San Francisco

About AUGX

augmedix is a telemedicine charting service for healthcare providers that eliminates the 17 hours each week providers spend on ehr documentation. using wearable technology to connect their clinic with the augmedix charting service, providers can focus on what they do best: taking care of patients.